Table 5. Cell biological feature related oncogenic functional connectivity map (pathway based) statistics.
| Name of Pathway | Network statistics |
|||||||
|---|---|---|---|---|---|---|---|---|
| CPN | CGH | CSV | CMG | CML | CIV | CAH | OVP | |
| Actin cytoskeletal regulation | N-7, E-7 | |||||||
| Adherens junction | N-8, E-9 | N-8, E-12 | N-9, E-10 | N-4, E-3 | N-8, E-13 | |||
| Alpha6 Beta4 mediated signaling | N-11, E-21 | N-6, E-6 | N-7, E-10 | |||||
| Androgen receptor mediated signaling | N-11, E-21 | N-12, E-24 | N-9, E-16 | N-7, E-8 | N-9, E-17 | N-3, E-2 | ||
| ARF6 trafficking event | N-16, E-31 | |||||||
| ATM dependent DNA damage response | N-8, E-9 | N-6, E-5 | ||||||
| Chemokine mediated signaling | N-11, E-18 | N-8, E-6 | N-8, E-8 | |||||
| Chronic myeloid leukemia pathogenesis | N-8, E-8 | N-6, E-5 | ||||||
| Class I PI3K mediated signaling | N-30, E-56 | N-21, E-28 | ||||||
| Colorectal cancer pathogenesis | N-8, E-9 | N-10, E-15 | N-4, E-3 | N-8, E-9 | ||||
| EGFR mediated signaling | N-8, E-7 | N-13, E-28 | N-3, E-2 | N-11, E-15 | ||||
| Estrogen receptor mediated signaling | N-31, E-59 | N-8, E-9 | N-10, E-10 | |||||
| Endometrial cancer associated pathogenesis | N-7, E-7 | |||||||
| ERBB mediated signaling | N-8, E-7 | N-11, E-18 | N-6, E-7 | |||||
| Focal Adhesion | N-9, E-11 | N-14, E-31 | N-8, E-8 | N-8, E-10 | N-9, E-13 | N-8, E-11 | N-4, E-4 | N-7, E-7 |
| Glioma associated pathogenesis | N-7, E-7 | |||||||
| HGF mediated signaling | N-8, E-10 | |||||||
| IGF1 mediated signaling | N-7, E-6 | |||||||
| IFN-gamma signaling | N-17, E-35 | N-10, E-14 | ||||||
| IL-2 mediated signaling | N-4, E-3 | |||||||
| IL-3 mediated signaling | N-11, E-21 | N-6, E-5 | N-9, E-11 | |||||
| IL-5 mediated signaling | N-10, E-15 | N-5, E-4 | ||||||
| IL-6 mediated signaling | N-13, E-27 | N-4, E-3 | N-6, E-6 | |||||
| IL-11 mediated signaling | N-6, E-5 | |||||||
| Insulin mediated signaling | N-6, E-5 | N-8, E-7 | ||||||
| Integrin mediated cell adhesion | N-7, E-10 | |||||||
| Kit receptor associated signaling | N-9, E-18 | N-5, E-4 | ||||||
| Leptin signaling | N-8, E-6 | N-9, E-11 | ||||||
| MAPK signaling | N-7, E-5 | N-6, E-5 | ||||||
| Melanoma pathogenesis | N-7, E-6 | |||||||
| Neurotrophin signaling | N-8, E-7 | N-5, E-5 | ||||||
| Oncostatin M signaling | N-7, E-8 | |||||||
| Pancreatic cancer pathogenesis | N-12, E-13 | N-6, E-5 | N-7, E-5 | N-5, E-3 | ||||
| p75(NTR) mediated signaling | N-8, E-7 | N-7, E-5 | ||||||
| Prolactin signaling | N-12, E-12 | N-10, E-15 | N-3, E-2 | |||||
| TGF beta associated signaling | N-9, E-8 | N-12, E-20 | N-8, E-6 | N-9, E-12 | N-8, E-9 | |||
| TRAIL signaling | N-9, E-9 | |||||||
| VEGF signaling | N-5, E-4 | N-6, E-5 | ||||||
| Wnt signaling | N-10, E-10 | N-8, E-8 | ||||||
| uPAR mediated signaling | N-21, E-28 | |||||||
Abbreviations: CPN-Cell proliferation, CGH-Cell growth, CSV-Cell survival, CMG-Cell migration, CML-Cell motility, CIV-Cell invasion, CAH-Cell adhesion, OVP-Overexpression, N-Node, number of protein present in the corresponding network, E-Edge, number of binary [physical] interactions between the proteins present in the corresponding network.